THE INVESTOR

메뉴열기
March 29, 2024

[EQUITIES] ‘Daewoong Pharma to thrive in Q1’

PUBLISHED : March 22, 2018 - 11:11

UPDATED : March 22, 2018 - 11:11

  • 본문폰트 작게
  • 본문폰트 크게
  • 페이스북
  • sms

[THE INVESTOR] Daewoong Pharmaceutical will reap strong earnings in the first quarter, said NH Investment and Securities on March 22, raising the target price to 270,000 won (US$253.21) from 220,000 won.




Its revenue on a standalone basis will reach 216 billion won with operating profit of 10.7 billion won, and it will advance in all sectors except OEM, said analyst Koo Wan-seong.

Sales of Nabota will surge 120 percent on-year to 4.4 billion won as its new factory for the drug began full operations since December last year, and exports of the drug to India will begin in the second quarter followed by US approval in the next quarter, according to the analyst. 

In the latter half, its R&D momentum will be highlighted, he added maintaining a “buy” recommendation. 

By Hwang You-mee (glamazon@heraldcorp.com)

  • 페이스북
  • sms
최상단으로
COPYRIGHT HERALD CORPORATION. ALL RIGHTS RESERVED.